MEDIUM confidence: 100% data completeness, but the composite (46) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Net insider -$14.2M over 180 days (0 open-market buys, 22 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Buy-rated share 65% → 67% over ~3 months (+2pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $2.09 | $2.29 | +9.6% |
| Jul 2026 | $2.09 | $2.47 | +18.2% |
| Apr 2026 | $2.11 | $2.56 | +21.3% |
| Feb 2026 | $1.38 | $1.80 | +30.4% |
| Oct 2025 | $0.79 | $0.85 | +7.6% |
| Jul 2025 | $0.54 | $0.57 | +5.2% |
| Apr 2025 | $0.62 | $0.75 | +21.2% |
| Jan 2025 | $0.91 | $0.95 | +4.4% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.7B— | $3.2B-14.8% | $2.7B-15.2% | $2.8B+5.4% | $3.2B+13.1% |
| EPS (dil.) | $5.53— | $4.22-23.7% | $2.73-35.3% | $3.32+21.6% | $3.48+4.8% |
| Free Cash Flow | $966M— | $415M-57.1% | $426M+2.6% | $474M+11.4% | $450M-5.0% |
| Gross Margin | 59.6% | 59.2%-0.4pp | 57.4%-1.8pp | 58.5%+1.1pp | 58.2%-0.3pp |
| Operating Margin | 32.4% | 26.4%-6.1pp | 18.7%-7.6pp | 21.1%+2.3pp | 20.4%-0.7pp |
| Net Margin | 27.4% | 22.7%-4.7pp | 16.8%-5.9pp | 19.2%+2.5pp | 17.4%-1.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 29.8%/yr (revenue basis).
Base free cash flow $450M (avg FY2023–FY2025; latest year $450M) · equity value $42.9B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 46 for Teradyne indicates a neutral outlook, driven by a mix of factors. The stock scores high on profitability, with a notable ROE of 42.0%, and exhibits strong value characteristics, trading at a P/E of 31.3. However, its growth score is pulled down by a decline in free cash flow growth, and its risk profile is elevated due to high volatility and a beta of 1.7. The long-term and short-term scores are relatively aligned, with only a 3-point difference.